A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

For more information about this side effect ... Otezla is approved for the treatment of moderate to severe plaque psoriasis in children ages 6 years and older. The drug is prescribed for this ...

Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

More information on Protagonist ... for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD ...

Patent protection for ZORYVE cream 0.3% extends until at least 2037. ZORYVE cream 0.3% is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

While nearly 8 million Americans live with plaque psoriasis, its impact is often unseen or covered up. 1 Art, whose music has touched millions worldwide, lived silently with his psoriasis—until now.